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ABSTRACT
Enteric fever is a broad term used to represent typhoid and paratyphoid fever which is caused by S. typhi and S. paratyphi respectively. The most 
common cause being S. typhi, overall. However, S. paratyphi is known to infect the travelers at a higher rate. Indian subcontinent being one of the most 
endemic region, it is always beneficial for the travelers to get immunized while traveling to these areas. However, Vaccination to S. paratyphi is not yet 
available, hence travelers often fall prey to the disease. The morbidity is often high but mortality is very rare, especially due to first line treatment drugs 
like ceftriaxone, nalidixic acid and floroquinolones (if patients are sensitive to it). Recently, it was observed that Multi-drug resistance (Resistance to at 
least ampicillin, chloramphenicol and trimethoprim-sulfamethoxazole]) was limited to Typhi isolates and was increased at an exponential rate. Hence, 
with increasing resistance to these drugs, developing vaccines or new drugs against these bacteria, remains an area of prime interest.
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INTRODUCTION
Enteric (typhoid or paratyphoid) fever is a systemic illness caused by 
Salmonella enterica serotype Typhi or S. enterica serotype Paratyphi. 
Salmonella typhi and S. paratyphi are highly adapted to humans and 
have no nonhuman animal or environmental reservoirs. Enteric 
fever is acquired by ingestion of fecally contaminated food and water. 
Continued excretion of a large number of bacteria by asymptomatic 
carriers or individual who have recently recovered from enteric fever 
is a common and is a major source of spread from an epidemic. In areas 
of endemicity, enteric fever is associated with drinking, contamination 
water, eating food prepared outside the home, having a close relative 
with enteric fever and poor housing. A recent study of Indonesia 
identified consumption of food from street vendors and flooding as 
being independently associated with paratyphoid fever [1]. In contrast, 
typhoid fever was associated with the household risk factor such as a 
presence of a household member with recent typhoid fever, lack of soap 
for hand washing, and sharing food from the same plate.
PATHOGENESIS
Genus Salmonella consists of Gram-negative bacilli that parasitize 
the intestinal tract of infected human beings. It was first observed 
by Eberth (1880) and was isolated by Gaffky (1884), so it also called 
Eberth-Gaffky bacillus. The most common cause of enteric fever is 
Salmonella typhi, hence the frequent use of the name typhoid fever. 
However, the similar clinical syndrome is also caused by S. paratyphi 
A, B and C. Thus, enteric fever is the more inclusive term. Reports 
from endemic countries demonstrate that S. typhi is the dominant 
pathogen, accounting for approximately 80% cases. In a report from 
Nepal, the ratio of S. paratyphi to S. typhi was 70% versus 30% among 
travelers, while this ratio was reversed as expected in the local 
population [2].
All pathogenic species of Salmonella, when arrive in the gut are engulfed 
by phagocytic cells, which then present them to the macrophages in 
the lamina propria after passing through the mucosa. Non-typhoidal 
salmonellae are phagocytized throughout the distal ileum and colon. 
With toll-like receptor (TLR)-5 and TLR-4/MD2/CD-14 complex, 
macrophages recognize pathogen-associated molecular patterns 
(PAMPs) such as lipopolysaccharides and flagella. Macrophages and 
intestinal epithelial cells then attract T cells and neutrophils which 
secrete interleukin 8, causing inflammation and suppressing the 
infection [3,4].
In contrast to the non-typhoidal salmonellae, S. typhi and Paratyphi 
enter the host’s system primarily through the distal part of ileum. 
They have specialized fimbriae that adhere to the epithelium over 
lymphoid tissue in the ileum (Peyer patches), the main relay point for 
macrophages traveling from the gut into the lymphatic system. The 
bacteria then induce their host macrophages to attract more and more 
macrophages [4].
S. typhi has a virulence (Vi) capsular antigen which masks PAMPs, 
avoiding neutrophil-based inflammation, while the most common 
Paratyphi like Paratyphi A, does not. This may explain the greater 
infectivity of typhi compared with the most of its other subtypes [5].
Typhoidal Salmonella uses the macrophages’ cellular machinery for 
their own reproduction [6] as they are carried from the mesenteric 
lymph nodes to the thoracic duct and the lymphatics and then through 
to the reticuloendothelial tissues of the liver, spleen, bone marrow, 
and lymph nodes. Once there, they pause and continue to multiply 
until some critical density is reached. Afterward, the bacteria induce 
macrophage apoptosis, breaking out into the bloodstream to invade the 
entire body [3].
The bacteria then infect the gallbladder via either blood route or direct 
extension of infected bile. The result is that the organism re-enters 
the gastrointestinal tract in the bile and re-infects the Peyer patches. 
Bacteria that do not re-infect the host are typically shed in the stool and 
are then available to infect other hosts [3,7].
EPIDEMIC FACTORS
Globally, each year, typhoid and paratyphoid fever, cause an estimated 
26 million and 5 million illnesses respectively [8]. The mortality is 
estimated at 2,15,000 annually [9]. The most cases are confined to 
the developing world, where the disease is endemic with the greatest 
burden being in the Indian subcontinent and South East Asia. In 
developing countries, enteric fever is a sporadic disease that occurs 
mainly in returned travelers. Overall, it has been estimated that 
the incidence of typhoid among traveler to developing countries is 
3-30 cases from 1,00,000 travelers [10]. The risk for traveler appears 
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to vary by geographic region visited. Several reports indicate that 
the Indian subcontinent has the higher risk of acquiring typhoid 
fever. A recent travel was reported by 74% of patient with typhoid 
fever reported to the United States Centre for Disease Control and 
prevention between 1994 and 1999 [11]. More than one-half of these 
patients had traveled to India subcontinent (Afghanistan, Bangladesh, 
Bhutan, India, Pakistan, Nepal, and Sri-Lanka), 17% travel to Mexico, 
8% to the Philippines and 5% had to Haiti. The overall risk of typhoid 
fever from travel to the Indian subcontinent is 18 times higher than 
from any other geographic area [12]. In another data, the attack rate 
of travel to Mexico is 2/1,00,000 journeys versus 10/1,00,000 to the 
Indian subcontinent [13]. In a British report, 75% cases of typhoid 
fever were in travelers and the authors, estimation of global risk of 
typhoid fever, i.e., the risk of contracting typhoid fever when travelling 
to all other developing countries besides the Indian subcontinent was 
1/1,00,000 visits, compared with 30 per 1,00,000 visits travel to the 
Indian subcontinent [14]. In 2013, 1,61,000 deaths occurred - down 
from 1,81,000 in 1990 [15]. Since few decades, the number of enteric 
fever cases acquired during international travel has substantially 
increased in the United States [12,16-18] and in other industrialized 
countries [19-22]. In one of the recent study conducted from 2008-
2012, 86% of typhoid cases were travel-associated [23], compared with 
79% during 1999 through 2006 [18].  The travel-associated percentage 
was even higher (91%) for paratyphoid fever [23].
RISK FACTORS FOR TRAVELERS
Risk factors for contracting enteric fever have been assessed by 
several authors. As expected, travel to rural areas with poor sanitation 
was associated with a higher risk. Not following food and water 
precautions and not receiving pre-travel consultation increased the risk 
10 times [24]. A German study found an increased risk among older 
travelers with a longer duration of stay (58 days vs. 19 days) [25]. In 
addition to more travel to rural areas, travelers visiting friends and 
relatives are less likely to have received pre-travel advice, less likely 
to food and water precautions and perhaps most importantly, by and 
large, do not perceive their risk or receive typhoid vaccine before travel.
CLINICAL MANIFESTATIONS
The clinical manifestation and severity of typhoid fever vary with the 
patient population studied. The most reports and textbook description 
related to study of a patient in endemic countries. Descriptions of 
the clinical presentation in travelers are scarce but an important 
difference in clinical manifestations exists between travelers to 
developing countries and local residents. These differences related to 
the likelihood of exposure to infection, age, and intensity of exposure, 
and may be affected by more rapid and readily available access to 
medical care. Most people with enteric fever present with a nonspecific 
febrile illness, often with an insidious onset, after an incubation 
period of 7-14 days (range 3-60 days). A headache, malaise, myalgia, 
and dry cough are common and the spleen enlarges. Arthralgia is less 
common for typhoid and paratyphoid fever than for rickettsial illness. 
The slowly increasing fever in a “stepladder” pattern is uncommon, 
although fever does not tend to worsen as the disease progresses. 
Often times, there are sudden episodes of shaking chills and rigor that 
resemble symptoms of fever due to malaria. Constipation and relatively 
bradycardia are common but necessary for the diagnosis. Rose spot 
(2-3 mm pink-red on the chest and abdomen) may appear, are often 
unnoticed, are often more prominent in cases of paratyphoid fever. 
The complication occurs in 10-15% of patients and probably are more 
common in patients who have ill for >2 weeks [26]. Gastrointestinal 
bleeding, intestinal perforation, and typhoid encephalopathy are 
the important complications. Travelers usually seek advice more 
promptly than do local patients, thus these complications are usually 
less common in the traveler population. Relapse occurs in 5-10% of 
patients, usually 2-3 weeks after the resolution of fever [3]. Relapses 
are typically milder than the original attack and the bacterial isolate 
from the relapse usually and has the same antibiotic susceptibility 
pattern as the original isolate. Importantly, 1-5% of patients with 
enteric fever long term, asymptomatic carriers who may shed S. typhi in 
either urine or stool for >1 year [26]. Chronic carriage rates are higher 
among women’s and among persons with biliary abnormalities such as 
gallstone. The chronic biliary carriage may occur in 2-5% of cases, even 
after treatment. The biliary carriage is defined as continued shedding of 
the organism for more than a year and is a public health risk, especially 
for infected individuals who work in the food industry.
The differential diagnosis in a traveler with suspected enteric fever 
is bored. Other considerations for patients returning from areas of 
endemicity with an undifferentiated febrile illness include malaria, 
rickettsial diseases (including murine and scrubs typhus), leptospirosis, 
dengue, hepatitis, and amebic liver abscess.
LABORATORY INVESTIGATIONS
The clinical diagnosis of enteric fever can be difficult because of 
nonspecific nature of symptoms and sign. A travel history to the Indian 
subcontinent or other areas of endemicity in a febrile patient should 
alert the physician to the possibilities of enteric fever. In a patient with 
enteric fever, the peripheral WBC count is usually normal to low and 
mild hepatic involvement may be reflected in slightly abnormal liver 
function test results. The definitive diagnosis of enteric fever requires 
the isolation of S. typhi and S. paratyphi from a specimen of blood, bone 
marrow or another extraintestinal site. Blood cultures are the standard 
diagnostic method, and the result can be positive in 60-80% in the 
1st week of fever. Blood culture is approximately 70% positive in the 
2nd week and it is negative on treatment with antibiotics. Feces cultures 
are almost as valuable as blood culture in the diagnosis of enteric fever. 
Urine culture is less useful than the culture of blood and feces; culture 
is generally positive in a second and the 3rd week and then only in 25% 
of cases. Bone marrow culture is valuable as it is positive in most cases 
even when blood cultures are negative. The culture of bile obtained by 
duodenal aspiration is usually positive and may be employed for the 
detection of carriers.
Several serological tests have been developed to detect S. typhi 
antibodies. The role of the Widal test is controversial with divergent 
views on the tests utility in various areas of endemicity. Newer rapid 
S. typhi antibody test (IgM and IgG) may be useful in areas where 
enteric fever is endemic and resources are limited [27]. A multiplex 
PCR (mPCR) assay was recently developed for the detection of multiple 
Salmonella serotypes in different kind of food products. This technique 
can be used regularly for the rapid detection of Salmonella species in 
the food materials even at low levels of contamination [28]. However, 
no current serological test is sufficiently sensitive or specific to replaced 
culture based tests for the diagnosis of enteric fever.
PREVENTION IN TRAVELERS
Hygiene, food and water precautions are a more important, especially 
for prevention of paratyphoid fever, as there is no vaccine available for 
this. Vaccinations further reduce the risk of typhoid fever in visitors 
to endemic areas but provide incomplete protection [25]. However, in 
a recent survey done in 2009-2011, it was noted that less than 50% 
of the patients were only vaccinated against typhoid [30]. Data on the 
effectiveness of typhoid vaccine in travelers are sparse, as the population 
has not been studied sufficiently [30]. It is especially important to give 
appropriate preventive information to travelers visiting friends and 
relatives where possible.
TREATMENT AND DRUG RESISTANCE
Historically, typhoid fever was treated with chloramphenicol, ampicillin, 
and co-trimoxazole. In 1972, chloramphenicol resistance becomes 
widespread and since 1989, resistance to all three has been noted in 
strains in India, China, and Pakistan [32]. Resistance appears to be 
plasmid mediated, allowing the simultaneous acquisition of resistance 
to multiple drugs and the emergency of multidrug resistance strains. 
50-80% of isolates from China and the Indian subcontinent are now 
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multidrug resistance [33] and 93% of the isolates in an outbreak in 
Tajikistan were multidrug resistance [34].
The introduction to fluoroquinolones was a major advance. The 
drugs were found to be highly effective, well-tolerated and could be 
administrated orally. Antibiotic such as ciprofloxacin quickly became 
the first-line agent. The treatment was also reduced from 14 days to 
as short as 5 days duration [35]. However, the increasing incidence of 
quinolones resistance is limiting the use of the class of the antibiotics. 
Ceftriaxone and other third-generation cephalosporins are a good 
choice of empirical therapy for travelers with suspected typhoid fever. 
An oral third-generation drug, cefixime has also been studied and found 
to be effective [3]. Drug resistance highlights an emerging crisis in the 
antibiotic treatment of enteric fever. Multidrug-resistant strains require 
expensive therapies that are less effective and result in higher stool 
carriage rates with a greater transmission potential, posing a public-
health risk, especially in countries where typhoid fever is endemic and 
by extension in travelers to these countries. One of the main reasons 
for the main emergency of fluoroquinolones resistant S. typhi and 
S. paratyphi in Asia is the widespread availability of relatively cheap, 
generic fluoroquinolones that can be purchased without a prescription. 
Azithromycin, which can be given orally, has shown promise in limited 
numbers of trials [36], with fever clearance times of 4-6 days and 
with rates of relapse and convalescent phase fecal carriage of <3%. 
Aztreonam and imipenem are expensive potential third-line drugs. Oral 
azithromycin was recently found to perform significantly better than 
ceftriaxone for the treatment of typhoid fever [37].
Despite demonstrating in vitro killing of salmonellae, first and second 
generation cephalosporins and an aminoglycoside are ineffective 
in treating enteric fever. A report of 113 S. typhi strains collected 
from India from 1987 to 2006, demonstrated possible “MIC creep” 
for ceftriaxone, though no frank resistance was observed. A gradual 
increase in ceftriaxone MIC has been observed in last 5-years 
increments: 0.047 mcg/ml, 0.098 mcg/ml, 0.211 mcg/ml, and 
0.365 mcg/mL for ceftriaxone MIC [38]. Gentamicin is widely used 
as therapy for Gram-negative sepsis. However, it is important to note 
that this antibiotic is not used empirically to treat Gram-negative 
bacteremia in patients who have recently been visiting areas where 
enteric fever is endemic.
Eradication of the chronic carrier state is important to stop the 
spread of the disease and can be achieved in >80% of cases with high 
dose ampicillin/amoxicillin with probenecid for 3 months or with 
ciprofloxacin for at least 4 weeks [26].
THE ADVENT OF TYPHOID VACCINES
The complex nature of the pathogenesis of S. typhi clinical infection 
has spurred the development of two primary types of vaccines. 
The parenteral vaccine takes advantage of the protective role of the 
circulating antibody response and lives attenuated oral vaccine rely 
on vigorous secretory IgA response and cell-mediated immunity to 
eliminate intracellular bacilli. Both vaccines are safe and well tolerated.
The live oral vaccine is an attenuated S. typhi strain, Ty21a which is 
mutual of Ty2 with a uridine diphosphogalactose 4-epimerase defect. 
The strain lacks the Vi antigen and is thus avirulent but contains 
immunogenic cell wall polysaccharides. Primary vaccination consists of 
one enteric coated capsule or lyophilized sachet on alternate days for 
3-4 doses. The live attenuated vaccine is theoretically contraindicated 
in pregnancy and in those with cell-mediated immunosuppression. 
In addition, the concurrent use of antibiotics and antimalarials 
may interfere with the antibody response. The vaccines need to be 
refrigerated, cannot to be given children under 6 years of age and relies 
on the traveler compliance and memory to complete the three to four 
required doses [39].
The Vi antigen is a capsular polysaccharide antigen that allows S. typhi 
to survive in the blood leading to septicemia. The parenteral Vi vaccine 
contains only the purified antigen and produces seroconversion 
following one dose. The vaccine is safe to be co-administered with other 
travel vaccines as well as antimalarials with no diminution in antibody 
response. However, because it is a polysaccharide, there is no boosting 
effect from revaccination and the duration of protection appears to 
be 2-3 years. Both the US Centre for Disease Control and Prevention 
and World Health Organization recommended typhoid vaccination 
for a person traveling to countries where enteric fever is endemic. 
These vaccines needed to be given at least 2 weeks before departure. 
Unfortunately, at present, there is no commercially available vaccine for 
the child travelers age <2 years.
Precautions which needed to be taken
The recent notification of S. typhi as a potential weapon of bioterrorism 
has helped to rekindle interest in important precautionary measures to 
help avoid infection with this organism. When traveling to the area of 
endemicity, travelers have to make sure that drinking water is boiled 
or properly bottled. Food should thoroughly cook preferably steaming 
hot when served. Fresh vegetables and fruits that have been washed in 
unclean water may be a source of infection. Breast-feeding of infants may 
need to be encouraged during travel to the area of endemicity. Clearly, 
eating food from street vendors is a risk for enteric fever, especially for 
enteric fever due to S. paratyphi A [1]. Finally, travelers visiting friends 
and relatives, especially those going to the Indian subcontinent need to 
be targeted for the prevention of enteric fever.
Prospective Treatment Options
An essential oil from Galangal (Alpinia galanga (Linn.) Pierre.) at a 
dose of 25 mg/ml, 50 mg/ml and 75 mg/ml was found to reduce the 
salmonella bacterial load in rats [40]. It was also observed that when 
antibiotics were attached with nanoparticles synthesized from Trametes 
sp. were found to be more effective against Salmonella species [41]. 
Also, methanolic extract of gyrocarpus asiaticus willd showed an 
effect in reducing the salmonella species [42]. A combination of plant 
extracts which includes Allium sativum (Amaryllidaceae), Szygium 
aromaticum (Myrtaceae), Berberis  aristata (berberidace), Rhus 
cotinus (Anacardiaceae) and phyllanthus emblica (Phyllanthaceae) also 
showed a positive effect in restricting Salmonella species [43].
CONCLUSION
Two features characterize enteric fever in industrialized countries. One 
is the general decline in the incidence of the disease, and the second 
is the concomitant rise in the percentage of travel related enteric 
fever. Most of the cases are acquired in the Indian subcontinent where 
multidrug resistance is the norm and where the fluoroquinolone 
resistance is on the rise. Vaccine efficacy is generally tested in endemic 
areas, which rises questions of how the result correlate with those in 
naive travelers and what contribution those already immune make to 
the trial result. The current vaccine offers only moderate protection 
against S. typhi and no protection against S. paratyphi, which has 
become dominant pathogen among travelers. Thus, there is a great 
Graph 1: Laboratory diagnosis of typhoid fever. The approximate 
percentage of tests found positive during different stages of the 
disease (week 1-8)[29]
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need for a combined vaccine, particularly with increasing antibiotic 
resistance in both S. typhi and S. paratyphi.
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